Pathophysiological mechanisms and evidence-based evaluation of extremely early in-hospital initiation of PCSK9 inhibitors in acute myocardial infarction
Historically, lipid management in acute myocardial infarction (AMI) has predominantly followed a statin-based stepwise titration strategy, causing many patients to miss their target lipid levels during the critical early risk window. Deeper research revealed that under the stress of acute ischemia and inflammatory microenvironments in AMI, PCSK9 exhibits a specific "extremely early burst", which impairs low-density lipoprotein cholesterol (LDL-C) clearance and directly drives pro-inflammatory macrophage polarization, endothelial barrier disruption, and microthrombosis through lipid-independent pathways. PCSK9 inhibitors achieve a dual blockade of this malignant pathological cascade by exerting strong lipid-dependent effects of lowering LDL-C and non-lipid pleiotropic effects of anti-inflammation and microcirculation protection. Recent clinical trials, including EVOPACS and EPIC-STEMI, substantiate that the extremely early in-hospital initiation of PCSK9 inhibitors (within 0-72 h of onset or periprocedurally during percutaneous coronary intervention) manifests a highly favorable safety profile concomitant with expedited lipid target attainment. Imaging studies, such as PACMAN-AMI, further demonstrated that early treatment can rapidly stabilize and promote the regression of vulnerable plaques, providing preliminary evidence that this strategy may reduce the short-term risk of recurrent cardiovascular events. Consequently, lipid-lowering pharmacotherapy is transitioning into a paradigm of "extremely early in-hospital initiation," effectively transcending conventional temporal therapeutic limitations. This review aims to systematically elucidate the stress-induced upregulation and pathophysiological mechanisms of PCSK9 within the acute AMI microenvironment, detail the dual interception mechanisms of PCSK9 inhibitors, and synthesize the clinical evidence base substantiating extremely early initiation over conventional therapeutic algorithms.
Authors
- Gang Pan (ORCID: https://orcid.org/0000-0003-4492-1963)
- Yujie Yan
- Shihao Huang
Institutions
- Jishou University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Yueyang Second People's Hospital (CN)
- Yueyang Hospital (CN)
Publication Details
- Journal
- Vessel Plus
- Published
- 2026-11-17
- DOI
- https://doi.org/10.20517/2574-1209.2026.63
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00